Zynex Stock Surges 40% After Delayed Q3 Filing and Earnings Call
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Zynex Inc (NASDAQ: ZYXI) is a Colorado-based medical device manufacturer specializing in non-invasive electrotherapy for pain management, physical rehabilitation, neurological diagnostics, and cardiac monitoring. Founded in 1996, the company develops and markets its products through three subsidiaries and trades on the NASDAQ exchange under the ticker ZYXI.
Corporate Structure
Zynex operates three primary business units:
- Zynex Medical: Home-use TENS/IFC/NMES devices for pain relief and functional rehabilitation.
- Zynex Monitoring Solutions: Non-invasive cardiac monitoring systems for hospitals (development stage).
- Zynex NeuroDiagnostics: Surface electromyography and autonomic measurement devices (development stage).
Headquartered in Englewood, Colorado, Zynex employs between 501 and 1,000 people. Thomas Sandgaard, founder and chairman since 1996, transitioned from day-to-day management when Steven Dyson assumed the role of chief executive officer on August 18, 2025.
Electrotherapy by Abby Anaday
Developments and News
- August 18, 2025: Steven Dyson joined Zynex as CEO; Thomas Sandgaard continues as chairman and chair of the technology committee.
- September 30, 2025: Quarter-end for fiscal Q3.
- November 12, 2025: Zynex filed a Notification of Late Filing (NT 10-Q) to notify the SEC of a delay in its Q3 financial statements, citing the need for additional time to finalize disclosures.
- November 17, 2025: The company submitted its Form 10-Q and an 8-K reporting current events under Items 2.02 and 9.01.
- November 18, 2025: Zynex held its Q3 earnings call.
- November 19, 2025: Shares traded at $0.5885, reflecting a 40.12% increase on a volume of 10,275,776 shares.
Financial and Strategic Analysis
As of September 30, 2025 (trailing twelve months):
| Metric | Value |
|---|---|
| Revenue | $144.81 million |
| Net Income (Loss) | –$28.66 million |
| Diluted EPS | –$0.93 |
| Profit Margin | –19.79% |
| Total Cash | $17.54 million |
| Total Debt/Equity | 5,746.23% |
| Price/Sales (TTM) | 0.12× |
| Enterprise Value/Revenue | 0.50× |
| Market Capitalization | $17.12 million |
| Enterprise Value | $72.13 million |
Key strategic priorities include advancing FDA-cleared products in electrotherapy, completing the development of cardiac monitoring and neurodiagnostic platforms, and optimizing reimbursement pathways. Investment research assigns Zynex a HOLD rating with a target price of $6.00; subratings are Medium (Industry, Growth), Low (Management, Safety, Financial Strength), and High (Value).
Market Position and Industry Context
Zynex operates in the medical equipment manufacturing sector and competes against larger electrotherapy and monitoring device firms. Its beta of 1.01 indicates that the stock's volatility aligns closely with broader market movements. A 52-week share range of $0.51–$8.72 shows significant past fluctuations. Average daily volume of 134,679 contrasts with the eleven-million-share surge on November 19, 2025. The company's small market cap and negative profitability metrics indicate challenges in scaling production and securing favorable payer mix, while value subratings suggest the stock trades at a discount relative to book value.
tl;dr
On November 19, 2025, ZYXI shares rose 40.12% to $0.5885 following its November 18 Q3 earnings call. The company had delayed its September 30, 2025 financials and filed an NT 10-Q on November 12. Trailing twelve-month revenue stands at $144.8 million with a net loss of $28.7 million. Analysts maintain a HOLD rating with a $6.00 target; future guidance will depend on reimbursement trends and advancements in cardiac monitoring and neurodiagnostics.